BioTelemetry

The healthcare industry is at a critical juncture, where every effort is being made to increase the effectiveness of care, while decreasing the financial burden on our system. With the introduction of BioTelemetry, we aim to lead in the advancement of mobile health monitoring by providing unmatched products and services to help healthcare professionals track and diagnose patients in a more efficient, accurate, and cost-effective manner. In April 2013, our predecessor company, CardioNet, Inc. (NASDAQ: BEAT), announced plans to adopt a holding company structure to more effectively facilitate our ongoing growth plans. With this change, our strategy is to achieve sustained long-term growth by solidifying our leadership position in remote cardiac monitoring, building a leading research services business, and identifying markets that would benefit from the application of our wireless platform and proprietary technology. We currently have four subsidiaries: CardioNet & Mednet- cardiac medical device & monitoring services, Braemar- cardiac manufacturing, Cardiocore- cardiac clinical research.
Type
Public
HQ
Malvern, US
Founded
2013
Size (employees)
938 (est)
Website
gobio.com
BioTelemetry was founded in 2013 and is headquartered in Malvern, US

BioTelemetry Office Locations

BioTelemetry has an office in Malvern
Malvern, US (HQ)
102 1000 Cedar Hollow Rd

BioTelemetry Metrics

BioTelemetry Financial Metrics

Revenue (2016)

$208.3 m

Revenue growth (2015-16), %

17%

Gross profit

$129.5 m

Gross profit margin (2016), %

62%

Net income (2016)

$53.4 m

Market capitalization (21-Mar-2017)

$765.4 m

Closing share price (21-Mar-2017)

$27.2

Cash (31-Dec-2016)

$23.1 m
BioTelemetry's current market capitalization is $765.4 m.
BioTelemetry's revenue was reported to be $208.3 m in FY, 2016 which is a 16.7% increase from the previous period.
FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$119 m$111.5 m$129.5 m$166.6 m$178.5 m$208.3 m

Revenue growth, %

(6%)16%29%7%17%

Cost of goods sold

$6.2 m$5.1 m$4.9 m$73.1 m$72 m$78.9 m

Gross profit

$112.8 m$106.4 m$124.6 m$93.5 m$106.6 m$129.5 m

Gross profit Margin, %

95%95%96%56%60%62%

Operating expense total

$86 m$97.8 m$97 m$111.4 m

EBIT

($6.9 m)($4.3 m)$9.5 m$18 m

EBIT margin, %

(5%)(3%)5%9%

Pre tax profit

($7.1 m)($12.1 m)$15.8 m

Income tax expense

$244 k($905 k)$215 k$37.7 m

Net Income

($7.3 m)($9.8 m)$7.4 m$53.4 m
Y, 2010Y, 2011Y, 2012Y, 2013Y, 2014Y, 2015FY, 2016

Cash

$18.7 m$18.3 m$18.3 m$22.2 m$20 m$19 m$23.1 m

Accounts Receivable

Inventories

$2.4 m$2.4 m$1.5 m$4.5 m

Current Assets

$44.3 m$49.5 m$47 m$59.6 m

PP&E

$18.8 m$21.7 m$25.6 m$25.8 m

Goodwill

$16.5 m$29.6 m$29.8 m$41.1 m

Total Assets

$87.5 m$124.8 m$124.1 m$199 m

Accounts Payable

$8.7 m$13.2 m$8.5 m$12.4 m

Total Debt

$23.2 m$25.3 m

Current Liabilities

$19 m$35.3 m$23.9 m$31.5 m

Additional Paid-in Capital

$260.6 m$267.2 m$272.1 m$281.6 m

Retained Earnings

($193.8 m)($203.6 m)($196.2 m)($142.7 m)

Total Equity

$66.8 m$63.7 m$75.9 m$138.9 m

Debt to Equity Ratio

0.3 x0.2 x

Debt to Assets Ratio

0.2 x0.1 x

Financial Leverage

1.3 x2 x1.6 x1.4 x
FY, 2013FY, 2014FY, 2015FY, 2016

Net Income

($7.3 m)($9.8 m)$7.4 m$53.4 m

Depreciation and Amortization

$12.3 m$12.6 m$12.5 m$14.3 m

Accounts Receivable

($4.6 m)($13 m)($7.7 m)

Inventories

$340 k$299 k$188 k($753 k)

Accounts Payable

$2.4 m$47 k($4.7 m)$3.1 m

Cash From Operating Activities

$11.3 m$8.8 m$14.4 m$38.9 m

Purchases of PP&E

($8.2 m)

Cash From Investing Activities

($8.2 m)($26.9 m)($13.6 m)($36.2 m)

Long-term Borrowings

($26.4 m)($1.4 m)

Interest Paid

$132 k$856 k$1 m$1.3 m

Income Taxes Paid

$112 k$148 k$384 k$359 k

BioTelemetry Market Value History

BioTelemetry News

BioTelemetry Company Life

You may also be interested in